Cargando…

Encapsulation of chloroquine and doxorubicin by MPEG-PLA to enhance anticancer effects by lysosomes inhibition in ovarian cancer

PURPOSE: As the deadliest gynecological malignancy, ovarian cancer ranks as a major cause of disease-related deaths to women worldwide and is treated with transurethral resection or systemic chemotherapy. However, traditional chemotherapeutic drug in antitumor therapy has shown unavoidable limitatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Ming, Zhu, Weitao, Lv, Xianping, Yang, Qiankun, Liu, Xin, Xie, Ying, Tang, Ping, Sun, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284531/
https://www.ncbi.nlm.nih.gov/pubmed/30584297
http://dx.doi.org/10.2147/IJN.S174300
_version_ 1783379349400977408
author Shao, Ming
Zhu, Weitao
Lv, Xianping
Yang, Qiankun
Liu, Xin
Xie, Ying
Tang, Ping
Sun, Ling
author_facet Shao, Ming
Zhu, Weitao
Lv, Xianping
Yang, Qiankun
Liu, Xin
Xie, Ying
Tang, Ping
Sun, Ling
author_sort Shao, Ming
collection PubMed
description PURPOSE: As the deadliest gynecological malignancy, ovarian cancer ranks as a major cause of disease-related deaths to women worldwide and is treated with transurethral resection or systemic chemotherapy. However, traditional chemotherapeutic drug in antitumor therapy has shown unavoidable limitations, such as poor curative effects, systemic toxicity and development of drug resistance, leading to failure of tumor inhibition and recurrence. This study aims to explore an innovative method to enhance the clinical efficiency of ovarian cancer. MATERIALS AND METHODS: Using MTT assay, the cell viability was detected under different culture systems. Western blot was used to examine the expression of P-gp in doxorubicin-resistant and wild-type A2780/SKOV3 cells. We used confocal to examine the drug concentration under different culture conditions. Also, flow cytometry was used to detect the drug absorption at the determined time points under different culture systems. Using nude mice model, we evaluated the killing efficacy of chemotherapeutic drugs with or without nanoparticle encapsulation. ELISA was used to examine the levels of creatinine, alanine aminotransferase and aspartate aminotransferase in plasma. RESULTS: We found that pretreatment of chloroquine (CQ) as chemosensitizer markedly enhanced the anticancer effects in ovarian cancer. We also provided evidence that CQ efficiently increase the pH value of lysosomes in tumor cells, leading to the reverse of drug sequestration induced by lysosomes. To further improve the pharmacokinetics profiles and avoid the systemic toxicity caused by chemotherapeutic agents, we encapsulated CQ and chemotherapeutic drugs by polymeric nanoparticles methoxy poly(ethylene glycol)-poly(l-lactic acid). Codelivery of CQ and chemotherapeutic agents by nanocarrier revealed enhanced anticancer effects compared with the free drug delivery by tail vein injection. More importantly, accumulated drugs, prolonged drug circulation and reduced organic damages were observed in nanoparticles delivery. CONCLUSION: Codelivery of CQ and chemotherapeutic drugs by methoxy poly(ethylene glycol)-poly(l-lactic acid) could significantly improve the anticancer effects and might have important potency in clinical applications for ovarian cancer therapy.
format Online
Article
Text
id pubmed-6284531
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62845312018-12-24 Encapsulation of chloroquine and doxorubicin by MPEG-PLA to enhance anticancer effects by lysosomes inhibition in ovarian cancer Shao, Ming Zhu, Weitao Lv, Xianping Yang, Qiankun Liu, Xin Xie, Ying Tang, Ping Sun, Ling Int J Nanomedicine Original Research PURPOSE: As the deadliest gynecological malignancy, ovarian cancer ranks as a major cause of disease-related deaths to women worldwide and is treated with transurethral resection or systemic chemotherapy. However, traditional chemotherapeutic drug in antitumor therapy has shown unavoidable limitations, such as poor curative effects, systemic toxicity and development of drug resistance, leading to failure of tumor inhibition and recurrence. This study aims to explore an innovative method to enhance the clinical efficiency of ovarian cancer. MATERIALS AND METHODS: Using MTT assay, the cell viability was detected under different culture systems. Western blot was used to examine the expression of P-gp in doxorubicin-resistant and wild-type A2780/SKOV3 cells. We used confocal to examine the drug concentration under different culture conditions. Also, flow cytometry was used to detect the drug absorption at the determined time points under different culture systems. Using nude mice model, we evaluated the killing efficacy of chemotherapeutic drugs with or without nanoparticle encapsulation. ELISA was used to examine the levels of creatinine, alanine aminotransferase and aspartate aminotransferase in plasma. RESULTS: We found that pretreatment of chloroquine (CQ) as chemosensitizer markedly enhanced the anticancer effects in ovarian cancer. We also provided evidence that CQ efficiently increase the pH value of lysosomes in tumor cells, leading to the reverse of drug sequestration induced by lysosomes. To further improve the pharmacokinetics profiles and avoid the systemic toxicity caused by chemotherapeutic agents, we encapsulated CQ and chemotherapeutic drugs by polymeric nanoparticles methoxy poly(ethylene glycol)-poly(l-lactic acid). Codelivery of CQ and chemotherapeutic agents by nanocarrier revealed enhanced anticancer effects compared with the free drug delivery by tail vein injection. More importantly, accumulated drugs, prolonged drug circulation and reduced organic damages were observed in nanoparticles delivery. CONCLUSION: Codelivery of CQ and chemotherapeutic drugs by methoxy poly(ethylene glycol)-poly(l-lactic acid) could significantly improve the anticancer effects and might have important potency in clinical applications for ovarian cancer therapy. Dove Medical Press 2018-12-03 /pmc/articles/PMC6284531/ /pubmed/30584297 http://dx.doi.org/10.2147/IJN.S174300 Text en © 2018 Shao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Shao, Ming
Zhu, Weitao
Lv, Xianping
Yang, Qiankun
Liu, Xin
Xie, Ying
Tang, Ping
Sun, Ling
Encapsulation of chloroquine and doxorubicin by MPEG-PLA to enhance anticancer effects by lysosomes inhibition in ovarian cancer
title Encapsulation of chloroquine and doxorubicin by MPEG-PLA to enhance anticancer effects by lysosomes inhibition in ovarian cancer
title_full Encapsulation of chloroquine and doxorubicin by MPEG-PLA to enhance anticancer effects by lysosomes inhibition in ovarian cancer
title_fullStr Encapsulation of chloroquine and doxorubicin by MPEG-PLA to enhance anticancer effects by lysosomes inhibition in ovarian cancer
title_full_unstemmed Encapsulation of chloroquine and doxorubicin by MPEG-PLA to enhance anticancer effects by lysosomes inhibition in ovarian cancer
title_short Encapsulation of chloroquine and doxorubicin by MPEG-PLA to enhance anticancer effects by lysosomes inhibition in ovarian cancer
title_sort encapsulation of chloroquine and doxorubicin by mpeg-pla to enhance anticancer effects by lysosomes inhibition in ovarian cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284531/
https://www.ncbi.nlm.nih.gov/pubmed/30584297
http://dx.doi.org/10.2147/IJN.S174300
work_keys_str_mv AT shaoming encapsulationofchloroquineanddoxorubicinbympegplatoenhanceanticancereffectsbylysosomesinhibitioninovariancancer
AT zhuweitao encapsulationofchloroquineanddoxorubicinbympegplatoenhanceanticancereffectsbylysosomesinhibitioninovariancancer
AT lvxianping encapsulationofchloroquineanddoxorubicinbympegplatoenhanceanticancereffectsbylysosomesinhibitioninovariancancer
AT yangqiankun encapsulationofchloroquineanddoxorubicinbympegplatoenhanceanticancereffectsbylysosomesinhibitioninovariancancer
AT liuxin encapsulationofchloroquineanddoxorubicinbympegplatoenhanceanticancereffectsbylysosomesinhibitioninovariancancer
AT xieying encapsulationofchloroquineanddoxorubicinbympegplatoenhanceanticancereffectsbylysosomesinhibitioninovariancancer
AT tangping encapsulationofchloroquineanddoxorubicinbympegplatoenhanceanticancereffectsbylysosomesinhibitioninovariancancer
AT sunling encapsulationofchloroquineanddoxorubicinbympegplatoenhanceanticancereffectsbylysosomesinhibitioninovariancancer